Helyx Industries enters the Next Generation Sequencing (NGS) market and joins Neonatal Screening project in Puglia
Helyx Industries (formerly Ulisse Biomed) announces its strategic entry into the Next Generation Sequencing (NGS) market. By establishing a dedicated division and securing a key partnership with Revvity Italia, the Group strengthens its position as a strategic player in advanced molecular diagnostics through its participation in the Genoma Project in Puglia.
A New Frontier in Molecular Diagnostics
The expansion into the NGS segment aligns with Helyx Industries' new industrial roadmap. The NGS market is experiencing rapid growth, with annual rates of 21-22% in Europe and Italy, and is projected to reach $14.7 billion in Europe by 2030.
Unlike traditional PCR, NGS technology allows for the simultaneous analysis of millions of DNA fragments, offering a significantly broader and more personalized range of genomic solutions.
"The entry into the Next Generation Sequencing market represents a strategic milestone for Helyx Industries. Our new NGS division was created to oversee a key technology for the future of diagnostics, capable of offering advanced and highly customizable solutions." > — Nicola Basile, CEO of Helyx Industries.
The Puglia Genoma Project: Excellence in Neonatal Screening
Through an agreement with Revvity Italia, Helyx Industries is collaborating on a universal neonatal screening program at the Di Venere Hospital in Bari. The project focuses on:
-
Analyzing newborn DNA to identify more than 400 metabolic disorders and rare diseases at an early stage.
-
Enabling early intervention with targeted clinical and therapeutic treatments.
-
Developing and producing custom screening kits based on specific clinical requirements.
Following a successful pilot phase in 2024, the project transitioned to a universal screening program in 2025.
Group Evolution: The Three Pillars of Helyx Industries
The rebranding from Ulisse Biomed to Helyx Industries reflects the Group’s industrial vocation and focus on scalability. The company now operates through three complementary divisions covering the entire molecular biology spectrum:
-
Mytho: The new NGS division, specialized in designing custom panels and advanced bioinformatics pipelines for clinical and research applications.
-
Hyris: Focused on qPCR and decentralized diagnostics via the Hyris System™, a patented integrated hardware and software platform.
-
Vytro: Dedicated to the development and production of PCR kits and IVD reagents for hospitals and diagnostic centers.
With headquarters in Milan and Udine, and R&D laboratories in Milan and Trieste, Helyx Industries holds a portfolio of 9 international patent applications, reinforcing its role as an innovator in the global biotech landscape.
